Prophylactic interventions for preventing macular edema after cataract surgery in patients with diabetes: A Bayesian network meta-analysis of randomized controlled trials

Ruiheng Zhang, Li Dong, Qiong Yang, Yueming Liu, Heyan Li, Wen‐Da Zhou, Haotian Wu, Yifan Li, Yitong Li, Chuyao Yu, Wenbin WeiEClinicalMedicine 2022 · DOI

TL;DR

Diabetic patients are at higher risk of vision-threatening macular edema after cataract surgery. This Bayesian network meta-analysis of 17 randomized controlled trials found that while both anti-VEGF injections and NSAIDs eye drops can reduce this risk, anti-VEGF also significantly improves visual acuity in the short term. This suggests anti-VEGF could be a valuable prophylactic option for this vulnerable patient group.

What Problem Does This Paper Address?

Cataract surgery is a common procedure, but for individuals with diabetes, it carries a significantly higher risk of developing postoperative macular edema (PME). PME can lead to reduced visual acuity and, in some cases, permanent vision loss, especially in diabetic patients who may already have compromised vision due to diabetic retinopathy. While various interventions exist to prevent PME, it's been unclear which are most effective, particularly when comparing different drug classes and delivery methods. This study aims to provide a comprehensive, evidence-based comparison of prophylactic interventions for PME in diabetic patients undergoing cataract surgery, focusing on both anatomical outcomes (PME occurrence) and functional outcomes (best-corrected visual acuity, BCVA).

Methods

The researchers conducted a Bayesian network meta-analysis, a powerful statistical technique that allows for the comparison of multiple treatments simultaneously, even if they haven't been directly compared in head-to-head trials. They searched major medical databases (MEDLINE, Embase, Web of Science) for randomized controlled trials (RCTs) published up to February 2022. The analysis included studies that reported PME events or BCVA outcomes in diabetic patients undergoing cataract surgery. The interventions compared were intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, nonsteroidal anti-inflammatory drugs (NSAIDs) eye drops, and topical steroids, all used as prophylactic measures. These were compared against a control group receiving placebo or topical steroid eye drops alone. The analysis assessed the odds ratios (ORs) for PME and mean differences (MDs) for BCVA at various time points (1 week, 1 month, 3 months, and 6 months post-surgery).

Datasets

The study did not introduce new datasets. Instead, it synthesized data from 17 previously published randomized controlled trials. The total number of participants across these trials was 2566.

Key Insights and Ideas

  • Diabetes as a Major Risk Factor: The paper reinforces that diabetes significantly elevates the risk of PME post-cataract surgery, with incidence rates increasing with the severity of diabetic retinopathy.
  • Beyond Direct Comparisons: Network meta-analysis is crucial for comparing interventions that haven't been directly pitted against each other in RCTs, offering a broader evidence base.
  • Short-Term Wins for Anti-VEGF: Intravitreal anti-VEGF injections show a clear advantage not only in preventing PME but also in improving visual acuity in the crucial first few months after surgery.
  • NSAIDs as a Solid Option for PME Prevention: Topical NSAIDs are effective in reducing the risk of PME, particularly at 1 and 3 months post-surgery, though they don't show the same visual acuity benefits as anti-VEGF.
  • Steroids' Role Less Clear: While topical steroids are a common intervention, their specific prophylactic benefit in this context, especially when compared to placebo or as an add-on, appears less pronounced than anti-VEGF or NSAIDs in this meta-analysis.

Key Results

  • PME Prevention:
    • At 1 month post-surgery, both topical NSAIDs (OR=0.221) and intravitreal anti-VEGF (OR=0.151) significantly reduced the risk of PME compared to placebo/steroid eye drops alone.
  • At 3 months post-surgery, this protective effect persisted for NSAIDs (OR=0.370) and anti-VEGF (OR=0.203).
  • At 6 months, these significant protective effects were not observed.
  • Visual Acuity (BCVA) Improvement:
    • At 1 month post-surgery, additional anti-VEGF showed a significant improvement in BCVA (MD = -0.083 LogMAR), equivalent to about 4.2 ETDRS letters.
  • At 3 months post-surgery, anti-VEGF continued to show a significant improvement (MD = -0.061 LogMAR), equivalent to about 3.1 ETDRS letters.
  • NSAIDs and other steroid interventions did not demonstrate significant BCVA improvements compared to the control group at any time point.
  • At 6 months, none of the interventions showed additional benefits for BCVA.

Limitations and Future Work

The authors acknowledge several limitations:

  • Heterogeneity in Interventions: The specific types of anti-VEGF agents (e.g., Bevacizumab, Ranibizumab) and NSAIDs varied across studies, limiting detailed subgroup analyses.
  • Control Group Variation: The control group sometimes included placebo and sometimes topical steroids, which could introduce some heterogeneity.
  • Blinding Issues: Due to the nature of eye drops and injections, participants and outcome assessors could not always be masked, potentially introducing bias. However, the authors argue that objective outcome measures (PME and BCVA) likely mitigated this.
  • Limited Data for Some Interventions: Data for intravitreal and sub-tenon steroids were limited, making it difficult to draw firm conclusions.
  • DR Severity Variation: While the study focused on diabetic patients, the severity of diabetic retinopathy varied across participants in different studies, which could influence susceptibility to PME.

Future work suggested includes:

  • Head-to-Head Trials: More direct comparisons between specific prophylactic interventions are needed to validate these findings.
  • Longer-Acting Steroids: Further research into the efficacy of longer-lasting intravitreal steroid formulations for PME prevention in diabetic patients is warranted.
  • Subgroup Analysis: Future studies could explore the differential effects of various anti-VEGF and NSAID agents, as well as investigate the impact of DR severity on treatment outcomes.
  • Precision Medicine: Incorporating OCTA findings and intraoperative complication data could help guide more precise application of interventions like anti-VEGF.

Summary updated

BibTeX
@inproceedings{zhang2022prophylactic,
  author = {Ruiheng Zhang and Li Dong and Qiong Yang and Yueming Liu and Heyan Li and Wen‐Da Zhou and Haotian Wu and Yifan Li and Yitong Li and Chuyao Yu and Wenbin Wei},
  title = {{Prophylactic interventions for preventing macular edema after cataract surgery in patients with diabetes: A Bayesian network meta-analysis of randomized controlled trials}},
  booktitle = {EClinicalMedicine},
  year = {2022},
  doi = {10.1016/j.eclinm.2022.101463},
}
Figure